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Abstract
Background: To assess the relationship between improved regional and global myocardial function in patients
with ischemic cardiomyopathy in response to b-blocker therapy or revascularization.
Materials and methods: Cardiovascular Magnetic Resonance (CMR) was performed in 32 patients with ischemic
cardiomyopathy before and 8 ± 2 months after therapy. Patients were assigned clinically to b-blocker therapy (n =
20) or revascularization (n = 12). CMR at baseline was performed to assess regional and global LV function at rest
and under low-dose dobutamine. Wall thickening was analyzed in dysfunctional, adjacent, and remote segments.
Follow-up CMR included rest function evaluation.
Results: Augmentation of wall thickening during dobutamine at baseline was similar in dysfunctional, adjacent and
remote segments in both patient groups. Therefore, baseline characteristics were similar for both patient groups. In
both patient groups resting LV ejection fraction and end-systolic volume improved significantly (p < 0.05) at
follow-up. Stepwise multivariate analysis revealed that improvement in global LV ejection fraction in the b-blocker
treated patients was significantly related to improved function of remote myocardium (p < 0.05), whereas in the
revascularized patients improved function in dysfunctional and adjacent segments was more pronounced (p <
0.05).
Conclusion: In patients with chronic ischemic LV dysfunction, b-Blocker therapy or revascularization resulted in a
similar improvement of global systolic LV function. However, after b-blocker therapy, improved global systolic
function was mainly related to improved contraction of remote myocardium, whereas after revascularization the
dysfunctional and adjacent regions contributed predominantly to the improved global systolic function.
Introduction
Recent estimations reveal that 4.9 million patients suffer
from chronic heart failure in the United States, indicat-
ing the magnitude of this major health care problem [1].
Ischemic cardiomyopathy is a frequent cause of chronic
heart failure. Different treatment options are available
for the treatment of ischemic cardiomyopathy, including
medical therapy and revascularization.
Beta-blocking agents have shown substantial benefit in
patients with various degrees of heart failure [2-4]. The
mechanisms by which b-blockers reduce mortality
among heart failure patients remain unclear. Heart fail-
ure is a complex disease that is characterized by chronic
excessive sympathetic nervous system stimulation caus-
ing myocardial toxicity and further depression of left
ventricular (LV) function [5]. It is suggested that LV
function improves after b-blocker therapy as a result of
reversal of catecholamine-mediated myocardial toxicity
in the partially viable or noninfarcted regions of the LV
and possibly by improving function in regions of
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hibernating myocardium [6]. It has been suggested that
dobutamine induced improvement in segmental con-
traction of dysfunctional myocardium before treatment
is related to improved global LV function after medical
therapy [7,8]. However, remote myocardium may poten-
tially also contribute to the improvement of LV function
after therapy, but this contribution has not yet been
evaluated.
The beneficial effect of revascularization of dysfunc-
tional myocardium in patients with ischemic cardiomyo-
pathy has traditionally been measured by its effect on
improvement of resting regional and global LV function
[9,10]. Revascularization is expected to improve regional
function when viable, but jeopardized myocardium is
present in an area of dysfunctional myocardium [11].
Furthermore, it has been recognized that LV end-systo-
lic volume predicts long-term outcome to best advan-
tage after revascularization [12].
Cardiovascular magnetic resonance (CMR) is a vali-
dated and reliable method to assess global and regional
myocardial function in normal and diseased hearts.
Functional CMR is well suited to assess resting wall
motion [13-17] as well as the response to dobutamine
for predicting viability of dysfunctional myocardial seg-
ments [18].
We sought to define the contribution of regional myo-
cardial segments to the improvement of global systolic
LV function in patients after medical therapy or revas-
cularization. We hypothesized that a differential effect
on regional myocardial segments occurs depending on
the type of therapy. Systemic medical therapy is
expected to have a more global effect on both ischemic,
dysfunctional myocardial segments and on non-
ischemic, remote myocardium, whereas revascularization
will have a more local effect on the ischemic, dysfunc-
tional myocardium depending on the territory of the
revascularized vessels.
Therefore, the purpose of the present study was to
assess the relationship between improved regional and
global myocardial function in patients with ischemic




Thirty-two patients with chronic ischemic cardiomyopa-
thy and LV ejection fraction (EF) <40% on gated resting
Tc-99m-SPECT, were included. All patients were in
sinus rhythm. Patients with a recent infarction (<3
months), unstable angina, valvular disease pacemakers
and/or intracranial clips were excluded.
Patients were included consecutively. Patients that did
not qualify for revascularization were assigned to the b-
blocker therapy group. Patients did not qualify for
revascularization because: 1. Patients had poor target
vessels (small vessels, not amendable for revasculariza-
tion) 2. Patients had prior existing co-morbidity (e.g.
renal failure); 3. Patients refused to undergo revasculari-
zation. b-blocker therapy was started at an initial dose
of 3.125 mg carvedilol twice daily. Subsequently, carve-
dilol was titrated at 1-week intervals as tolerated, up to
target dose of 25 mg twice daily [19].
b-Blocker treated patients were compared to patients
who underwent revascularization. In the revasculariza-
tion patients, coronary artery bypass surgery was per-
formed in 75% and percutaneous coronary intervention
in 25%. Each patient gave informed consent to the study
protocol that was approved by the local ethics
committee.
CMR acquisition
Patients were studied by CMR before therapy and at 8
± 2 months after therapy. At baseline, the CMR proto-
col consisted of a resting cine CMR, Late Gadolinium
Enhancement (LGE) and low-dose dobutamine (10 μg/
kg/min) cine CMR. Follow-up CMR included rest func-
tion evaluation only. The congestive heart failure classi-
fication by the New York Heart Association (NYHA)
was determined at baseline and follow-up by the
patient’s cardiologist, who was blinded to the CMR
data.
A 1.5-Tesla Gyroscan ACS-NT CMR scanner (Philips
Medical Systems, The Netherlands) and a 5 elements
cardiac synergy coil were used. Patients were studied in
supine position. All images were acquired during
breath-holds of approximately 15 seconds and were
gated to the vector ECG; blood pressure was monitored
continuously during the examination (Millennia, Invivo
Research, Orlando Fla, USA). The heart was imaged
from apex to base with 10 to 12 imaging levels (depen-
dent on heart size) in short-axis view using a steady-
state free-precession sequence. Typical acquisition para-
meters were: field of view 400 × 400 mm2, matrix size
256 × 256, slice thickness 10.00 mm, flip angle 50°, time
to echo 1.82 ms and time to repeat 3.65 ms. Temporal
resolution was 25-39 ms, depending on heart rate. Geo-
metry settings of rest cine CMR scans were stored and
repeated for LGE and low-dose dobutamine stress
CMR.
LGE images were acquired approximately 15 minutes
after bolus injection of gadopentate dimeglumine (Gado-
linium-DTPA, Magnevist, Schering/Berlin, Germany,
0.15 mmol/kg) with an inversion-recovery gradient echo
sequence; inversion time was determined using real time
planscan. Typical parameters were the following: field of
view 400 × 400 mm2, matrix size 256 × 256, slice thick-
ness 5.00 mm, slice gap - 5 mm, flip angle 15°, time to
echo 1.36 ms and time to repeat 4.53 ms.
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For evaluation of myocardial function under pharma-
cological stress, intravenous dobutamine infusion was
started at a rate of 5 μg/kg/min and increased after 5
min to 10 μg/kg/min. Then, after 5 min (at steady
state), low-dose dobutamine images were acquired in 2-
and 4-chamber and short-axis views. The same para-
meters were applied as described for rest imaging.
CMR image analysis
Data were analyzed on a remote workstation using
MASS software (MASS, Medis, The Netherlands). The
endo- and epicardial borders of the end-diastolic and
end-systolic frames were manually traced with exclusion
of papillary muscles, trabeculae, and epicardial fat [20].
LV end-diastolic and end-systolic volumes were calcu-
lated and LVEF was derived.
The amount of infarcted tissue was determined by
drawing (manually) regions of interest around the scar
tissue. In addition, the percentage of myocardium was
calculated that was affected by infarction, relative to the
total LV mass. LGE images were scored visually by two
experienced observers (blinded to other CMR and clini-
cal data) using a 17-segment model. Each segment was
graded on a 5-point scale (segmental scar score) with 0:
absence of LGE, 1: LGE of 1-25% of LV wall thickness,
2: LGE extending to 26-50%, 3: LGE extending to 51-
75%, and 4: LGE extending to 76-100% of the LV wall
thickness [21].
To determine regional wall motion at rest, cine CMR
images were visually interpreted by two experienced
observers (blinded to other CMR and clinical data)
using a 17-segment model. Each segment was assigned a
wall motion score using a 5-point scale with 0: normal
wall motion, 1: mild hypokinesia, 2: severe hypokinesia,
3: akinesia, and 4: dyskinesia [22]. In the dysfunctional
segments at rest (score 1-4), the presence or absence of
contractile reserve was based on visual analysis of the
difference in myocardial wall motion between CMR
acquisitions at rest and during infusion of low-dose
dobutamine. An improvement in segmental wall motion
score by 1 grade or more was considered indicative of
contractile reserve.
Myocardial segments with a visual wall motion score
at rest from 1 to 4 were considered as dysfunctional
segments. The myocardial segments next to these dys-
functional segments in 3-dimensions, were considered
as adjacent segments. The remaining myocardial seg-
ments were considered as remote tissue (Figure 1).
Wall thickness was then quantified in the above
defined three regions: (1) dysfunctional, (2) adjacent,
and (3) remote segments, using the centerline method
as described before [23]. Wall thickening was calcu-
lated based on the difference in wall thickness between
end-diastole and end-systole. The change in wall
thickening was calculated between baseline and dobu-
tamine stress acquisitions, or between baseline and fol-
low-up acquisitions.
Statistical analysis
Continuous data were expressed as mean ± SD and
compared using the Student’s t test for (un-) paired data
when appropriate. Stepwise multivariate analysis was
performed to determine the relation between regional
improvement in myocardial function and improvement
in global LVEF at follow up. All tests were two-tailed
and a P-value < 0.05 was considered statistically
significant.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agree to the manuscript as written.
Results
Baseline
Baseline characteristics are summarized in Table 1. The
variables listed in Table 1 were not statistically signifi-
cantly different between patients in the b-blocker and
revascularization groups (Table 1). Table 2 summarizes
LV dimensions and global systolic function. At baseline,
there were no statistically significant differences between
both patient groups (Table 2). Table 3 shows scar bur-
den and scar morphology. At baseline, there were no
statistically significant differences between both patient
groups (Table 3).
The response to low-dose dobutamine at baseline in
the dysfunctional, adjacent, and remote myocardial seg-
ments is summarized in Figure 2 (left panel). There
were no statistically significant differences in wall thick-
ening in any myocardial segment, when comparing the
b-blocker and revascularization groups at baseline (Fig-
ure 2).
Follow-up after b-blocker or revascularization therapy
Clinical assessment revealed that the NYHA classifica-
tion changed from 2.3 ± 0.5 at baseline to 1.8 ± 0.6 at
follow-up (P < 0.05) in the b-blocker treated patients,
and from 2.2 ± 0.5 to 1.5 ± 0.5 in the revascularization
patient group (P < 0.05). After b-blocker or revasculari-
zation therapy, LV end-diastolic volume did not change
significantly in both patient groups while LV end-systo-
lic volume and LVEF improved significantly in both the
b-blocker and revascularization groups to the same
extent (Table 2).
Comparison of myocardial wall thickening between
follow-up and baseline, revealed that in the b-blocker
group the remote segments showed the largest improve-
ment (Figure 2, right upper panel). Stepwise multivariate
analysis in b-blocker patients revealed that improvement
in LVEF after therapy was mainly related to
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improvement in function of the remote region (y = 2 ×
Rmt + 1.8, where Rmt = difference in wall thickening at
rest in remote tissue between follow-up and baseline, P=
0.002, acceptance value 0.05). In the revascularization
patient group, most improvement in myocardial wall
thickening between follow-up and baseline was achieved
in the dysfunctional segments (Figure 2, right lower
panel). Stepwise multivariate analysis in revasculariza-
tion patients revealed that improvement in LVEF was
mainly related to improvement in function of the dys-
functional and adjacent segments (y = 2.6 × Dsf + 1.8 ×
Adj + 0.6, where Dsf = difference in wall thickening at
rest in dysfunctional segments between follow-up and
baseline, Adj = difference in wall thickening at rest in
adjacent segments between follow-up and baseline, P=
0.001, acceptance value 0.05).
Direct comparison between the b-blocker and revascu-
larization groups concerning the myocardial segments
shows a statistically significant difference (P < 0.05) in
wall thickening between the dysfunctional and remote
segments (Figure 2 right panel, top and bottom). As a
consequence, a reversed pattern is observed in the
Figure 1 Diagram in 3D showing the relative position in a virtual left ventricle of the three regions that were quantified using the
centreline method. Definition of segments was based on a visual wall motion score using a 17-segment model and a 5-point scoring system
with 0: normal wall motion, 1: mild hypokinesia, 2: severe hypokinesia, 3: akinesia, and 4: dyskinesia. Myocardial segments with a visual wall
motion score from 1 to 4 were considered as dysfunctional segments (grey). The myocardial segments next to these dysfunctional segments in
3-dimensions, were considered as adjacent segments (dashed). The remaining myocardial segments were considered as remote tissue (white).
Kaandorp et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:7
http://www.jcmr-online.com/content/12/1/7
Page 4 of 9
contribution of the dysfunctional and remote myocardial
segments to improvement in wall thickening after b-
blocker or revascularization therapy. This differential
pattern is also illustrated in Figure 3, showing the rela-
tive contributions of the myocardial segments to
improvement in LVEF after b-blocker or revasculariza-
tion therapy. In the b-blocker treated patients (Figure 3,
top), the remote tissue contributes for 60% to the
improvement in LVEF, whereas in the revascularized
patients (Figure 3, bottom), the dysfunctional segments
contributed for 56% to the improvement in LVEF after
therapy.
Discussion
The present study demonstrates the relation between
regional and global myocardial function in patients with
ischemic cardiomyopathy after b-blocker or revasculari-
zation therapy. Following b-blocker therapy, improved
global systolic function is mainly related to improved
contraction of remote myocardium, whereas after revas-
cularization the dysfunctional and adjacent regions
contributed most to the improvement in global systolic
function.
Baseline
At baseline, NYHA classification was similar for b-
blocker treated and revascularization patients. In addi-
tion, global systolic function, the % scar tissue or the
number of segments with contractile reserve were simi-
lar in both patient groups at baseline. Furthermore, both
patient groups showed the same response to low-dose
dobutamine at baseline in the dysfunctional, adjacent,
and remote myocardial segments. Accordingly, the clini-
cally defined patient groups were comparable at baseline
concerning myocardial function.
Follow up after b-blocker or revascularization therapy
Following b-blocker or revascularization therapy, LV
systolic function improved significantly, and to a similar
extent. Accordingly, the global functional response to
Table 1 Baseline characteristics of the study population
b-Blocker therapy Revascularization
(n = 20) (n = 12)
Age (yrs) 67 ± 8 68 ± 6
Gender (male/female) 20/0 11/1
Time to follow-up (months) 8 ± 3 9 ± 4
Nr of stenosed (> 70%) coronary arteries 2.7 ± 0.5 2.5 ± 0.5
Nr of segments with contractile reserve 5.5 ± 3.2 3.7 ± 1.7
NYHA classification 2.3 ± 0.5 2.2 ± 0.5
Medication:
Asperin 95% 100%
Angiotensin converting enzyme inhibitors 65% 58%
Diuretics 55% 50%
Nitrates 35% 50%
Nr of segments with:
Dysfunctional tissue 7.4 ± 3.2 5.5 ± 1.5
Adjacent tissue 6.3 ± 2.0 6.5 ± 1.1
Remote tissue 3.4 ± 2.6 5.1 ± 2.0
All comparisons between both groups were statistically non-significant.
Table 2 Effect of therapy on left ventricular dimensions
and global systolic function
b-blocker therapy Revascularization
Baseline Follow-up Baseline Follow-up
LVEDV (ml) 271 ± 63 254 ± 55 238 ± 48 250 ± 59
LVESV (ml) 190 ± 63 163 ± 54* 152 ± 35 140 ± 41*
LVEF (%) 31 ± 7 37 ± 9* 36 ± 6 44 ± 6*
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-
diastolic volume; LVEF: left ventricular ejection fraction.
*: P < 0.05 for baseline versus follow-up values. Other comparisons were non-
significant.
Table 3 Scar morphology at baseline.
b-blocker therapy Revascularization
Scar tissue on LGE CMR (g) 31.9 ± 18 29.5 ± 15.0
Scar tissue on LGE CMR (%) 19.6 ± 10.9 17.1 ± 7.5
Nr of segments with:
LGE score 0 8.8 ± 3.9 10.6 ± 1.9
LGE score 1 3.9 ± 3.1 2.8 ± 2.4
LGE score 2 1.9 ± 1.6 1.2 ± 1.1
LGE score 3 1.5 ± 1.6 1.7 ± 1.8
LGE score 4 1.0 ± 1.4 0.8 ± 1.2
LGE Score: 0: absence of LGE, 1: LGE of 1-25% of LV wall thickness, 2: LGE
extending to 26-50%, 3: LGE extending to 51-75%, and 4: LGE extending to
76-100% of the LV wall thickness. There were no statistically significant
differences between both patient groups.
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therapy was comparable between both patient groups.
This finding is consistent with results from previous stu-
dies [5,6,9,12,24,25]. Furthermore, improvement in LVEF
was accompanied by an improvement in NYHA classifi-
cation from baseline to follow up, to a similar extent in
both patient groups.
Stepwise multivariate analysis in b-blocker patients
revealed that improvement in LVEF after therapy was
mainly related to improvement in function of the
remote myocardium. The present results concerning b-
blocker therapy effect on remote tissue are in agreement
with previous studies by Reiken et al. Both in a canine
model [26] and in a patient study (performed in
explanted hearts) [27], the authors showed that b-block-
ers normalized Ca++-channel function in failing myocar-
dium. Remote myocardium in the current study may be
regarded as myocardium with relatively preserved myo-
cyte function as compared to adjacent and dysfunctional
regions.
However, in remote tissue, myocardial hypertrophy
may develop when excessive pressure or volume over-
load is imposed to sustain the burden of a dysfunctional
segment [28]. The remote hypertrophied tissue may
appear to contract normally, but could in fact represent
“pseudonormalized” myocardium. Therefore, the rela-
tively mildly failing remote myocardium can still show a
positive response to restoration of the Ca++-channel
function by administration of b-blockers, whereas the
adjacent and dysfunctional tissue cannot. Furthermore,
recent data demonstrated that the effect of b-blocker
therapy could be predicted by the increase in LVEF dur-
ing low-dose dobutamine infusion [29]. Since
Figure 2 Changes in wall thickening from baseline to low-dose dobutamine (left panel) or from baseline to follow-up (right panel) for
patients treated with b-blockers (upper panel) or undergoing revascularization (lower panel). Note the similarity in regional distribution
when comparing dobutamine-baseline measurements of both patient groups. In addition, note that the regional distribution is similar in
response to dobutamine or b-blocker therapy. Moreover, in patients treated with b-blockers, the remote tissue contributed predominantly to
overall wall thickening, whereas after revascularization the dysfunctional segments contributed most to the observed changes in systolic wall
thickening. *: P ≤ 0.05 for b-blocker therapy and revascularization.
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dobutamine is a b-receptor agonist, it may be able to
temporarily mimic sympatic nervous system stimulation,
and predict the effect of b-blockers on LVEF. Interest-
ingly, the regional response pattern after b-blocker ther-
apy in the current study (Figure 2, right upper panel) is
similar to the regional response to dobutamine in b-
blocker treated patients (left upper panel). The latter
observation supports the hypothesis that low-dose dobu-
tamine infusion in patients with chronic ischemic LV
dysfunction may predict clinical outcome after b-blocker
therapy [29].
Stepwise multivariate analysis in revascularization
patients revealed that improvement in LVEF was mainly
related to improvement in function of the dysfunctional
and adjacent myocardial segments. This observation is
in agreement with data obtained in previous studies
[30,31]. Recovery of hibernating myocardium occurs
after successful revascularization [11,32,33]. In the pre-
sent study, no improvement in wall thickening was
noted in the remote region in the revascularization
patients. The latter finding may be explained by the fact
that only blood flow to dysfunctional and surrounding
adjacent tissue is restored. As a result, no short-term
improvement in function can be expected in the remote
area. An interesting finding in the present study was
that adjacent myocardium also contributed significantly
to the improvement of global systolic function after
revascularization therapy.
Linitations
The number of patients was relatively small and there-
fore the observations need confirmation in larger
Figure 3 Relative contributions of dysfunctional, adjacent and remote tissue to overall systolic wall thickening changes after therapy.
Note the inverse regional contributions: remote tissue contributed most to the effect of b-blocker therapy, whereas dysfunctional segments
contributed mainly to the effect of revascularization.
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cohorts. Myocardial tagging was not performed; this
could have provided a more detailed strain assessment
across the myocardial segments of interest.
Conclusion
In patients with chronic ischemic LV dysfunction, b-
Blocker therapy or revascularization resulted in a similar
improvement of global systolic LV function. However,
after b-blocker therapy, improved global systolic func-
tion was mainly related to improved contraction of
remote myocardium, whereas after revascularization the
dysfunctional and adjacent regions contributed predomi-
nantly to the improved global systolic function.
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